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Abstract: Despite advances in surgical cytoreduction and cytotoxic chemotherapy, ovarian 
cancer continues to be the leading cause of death in women with gynecologic malignancy. 
Our understanding of the treatment of ovarian cancer was revolutionized with the discovery of 
platinum- and taxane-based adjuvant chemotherapy regimens. Since that time however, overall 
survival has been stable. Given the above, an emphasis has been placed on exploring alternative 
therapeutics. Recent research efforts have improved our understanding of the molecular biology 
of ovarian cancer and novel targeted treatment strategies have emerged. The most studied of these 
agents has been the monoclonal anti-vascular endothelial growth factor antibody bevacizumab. 
The purpose of this review is to discuss management issues related to the treatment of ovarian 
cancer, with a focus on the utilization of bevacizumab, summarizing applicable clinical trials, 
its potential benefits, and reported adverse events.
Keywords: bevacizumab, ovarian cancer, molecular targeted therapy, VEGF, angiogenesis
Introduction
Epithelial ovarian cancer (EOC) accounts for 25% of all malignancies affecting the 
female genital tract, and is the most lethal gynecologic malignancy. In the United States 
alone, a projected 21,880 new cases will be diagnosed, with 13,850 deaths.1 Advanced 
stage epithelial ovarian cancer is traditionally managed with surgery, f  ollowed by 
chemotherapy consisting of platinum and taxane.2 Patients with advanced disease who 
undergo successful cytoreductive surgery have a median survival of just over 4 years 
after completion of adjuvant chemotherapy.3 Unfortunately, the majority of these 
patients develop recurrent cancer, with selection of chemotherapy resistant clones.4
More recently, targeted therapies have been explored in the treatment of   ovarian 
cancer and various potential therapeutic pathways, and biologic therapies have 
emerged. Specifically, anti-angiogenic agents have been the most studied and effective 
in the treatment of ovarian cancer. Angiogenesis is essential for tumor invasion and 
metastasis, and is required for tumor growth beyond 1–2 mm.5 This process requires 
the recruitment of vasculature and circulating endothelial cells, and pro-angiogenic 
mediators including vascular endothelial growth factor (VEGF). Ovarian cancer 
patients with elevated VEGF levels have been shown to have poorer overall prognosis, 
with VEGF levels being independent indicators of survival.
To date, bevacizumab, a recombinant human monoclonal antibody to the VEGF 
ligand, has been the most studied anti-angiogenic agent. The immediate mechanism of 
action of bevacizumab is to bind and inactivate VEGF, thereby inhibiting endothelial, 
and possibly tumor, cell activation and proliferation.6 In addition to denying tumors of Biologics: Targets and Therapy 2011:5 submit your manuscript | www.dovepress.com
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nutrients, VEGF inhibition has been shown to induce   vascular 
normalization, and to restore normal structure, function, 
and flow to the disorganized, leaky vessels characteristic 
of malignant tumors. These changes result in improved 
delivery of oxygen, nutrients, and cytotoxic chemotherapy 
to the tumor.7
Bevacizumab was first studied in patients with clear 
cell renal cell cancer, because of its unique VEGF-driven 
  biology, and 4 other common solid tumors with high 
t  herapeutic need; colon, prostate, lung, and breast   cancers.8 
Phase III   bevacizumab trials were then conducted in 
  metastatic   colorectal cancer (mCRC),9 metastatic nonsmall 
cell lung cancer (mNSCLC),10 and metastatic breast cancer 
(mBC),11 all of which met their primary endpoints, thus 
s  upporting Food and Drug Adminstgration (FDA) approval 
of b  evacizumab for these indications.12 One of the next 
opportunities for approval will be in epithelial ovarian and 
primary peritoneal carcinomas.
Current treatment regimens  
in ovarian cancer
Currently, patients presenting with advanced stage o  varian 
cancer are managed with surgical resection followed 
by adjuvant platinum- and taxane-based chemotherapy. 
Our understanding of the therapeutic benefits of this regimen 
originated following the results of Gynecologic Oncology 
Group (GOG) protocol 111.13 This randomized trial illus-
trated an improvement in both progression free survival (PFS) 
and overall survival (OS) in patients treated with cisplatin and 
paclitaxel, in comparison to those treated using cisplatin 
and cyclophosphamide (PFS 18 vs 13 months, OS 38 vs 
24 months, respectively). This study offered justification for 
a major change in the treatment of ovarian cancer.
Following completion of GOG 111, the GOG opened 
protocol 158.3 This was designed as a noninferiority trial 
comparing carboplatin and paclitaxel with cisplatin and 
paclitaxel. In previous nonrandomized trials the combination 
of carboplatin and paclitaxel was shown to be a less toxic 
and highly active combination regimen in the treatment of 
ovarian cancer. Ozols et al enrolled 792 eligible patients, with 
results showing decreased gastrointestinal, renal, and meta-
bolic toxicities as well as decreased grade 4 leukopenia in 
the carboplatin-containing arm.3 Median PFS and OS did not 
differ significantly between study groups. The authors thus 
concluded that the combination of carboplatin and paclitaxel 
was less toxic, easier to administer, and not inferior to the 
previous standard of cisplatin and paclitaxel. Furthermore, 
in patients who were optimally cytoreduced (residual disease 
at completion of surgery ,1.0 cm) the median survival was 
nearly 5 years in the carboplatin-containing arm.
In addition to intravenous (IV) therapy, the GOG also 
investigated intraperitoneal (IP) treatment options. GOG 
p  rotocol 172 was designed to compare IV paclitaxel 
(135 mg/m2) over 24 hours with IV cisplatin (75 mg/m2) on 
day 2, vs IV paclitaxel (135 mg/m2) over 24 hours,   followed 
by IP cisplatin (100 mg/m2) on day 2 and IP paclitaxel 
(60 mg/m2) on day 8. A total of 6 courses would be admin-
istered every 3 weeks.14 All patients had optimally resected 
disease with residual tumor limited to less than or equal to 
1 cm in size. The median survival for the IV and IP arms were 
49.5 and 66.9 months respectively. The relative risk (RR) 
of death was 0.71 in the IP group (P = 0.0076). The authors 
however noted that tolerability for IP chemotherapy was a 
concern as grade 3 and 4 hematologic, metabolic, and gas-
trointestinal toxicities were significantly more common in 
the IP arm. In fact, only 42% of patients allocated to the IP 
arm completed 6 cycles of chemotherapy.
Unfortunately, despite the above advances in up-front 
adjuvant chemotherapy, disease recurrence continues to be 
problematic. Patients with recurrent disease are uncommonly 
cured, and thus comprise a population of patients for whom 
clinical trials and investigations into alternative therapies 
may be beneficial. Patients with disease recurrence 6 months 
after first-line therapy are termed “platinum sensitive”, and 
have response rates in the range of 30%–40% to second-line 
agents.15 These patients typically receive a platinum-based 
regimen, often in combination with paclitaxel, gemcit-
abine, or pegylated liposomal doxorubicin.16 On the other 
hand, patients with disease recurrence within 6 months of 
up-front therapy, termed platinum resistant, and those with 
disease persistence/progression while on first-line platinum 
therapy, termed platinum refractory, are typically treated with 
  nonplatinum-based regimens.15 Agents that can be considered 
in this setting include liposomal doxorubicin, topotecan, 
gemcitabine, and oral etoposide.17
Bevacizumab
As described above, despite multimodal chemotherapy after 
surgical cytoreduction, the minority of women with ovarian 
cancer are actually cured. Thus, exploration of alternative 
therapeutics has been a priority. Specifically, the study of 
angiogenesis in ovarian cancer, and the role of potential 
modulators of angiogenesis in its treatment have emerged as 
a promising strategy.18 Angiogenesis is the process of new Biologics: Targets and Therapy 2011:5 submit your manuscript | www.dovepress.com
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blood vessel development and is essential for tumor growth 
beyond 100–200 µm. This process is mediated through the 
VEFG family of growth factors and receptors. The immediate 
action of bevacizumab, the first FDA-approved monoclonal 
anti-angiogenic antibody, is to bind and inactivate VEGF, 
inhibiting endothelial cell proliferation and activation. The 
utility of VEGF in the treatment of ovarian carcinoma was 
initially explored in animal models, where VEGF blockade 
was shown to inhibit ascites formation and slow tumor 
growth.19 Numerous retrospective clinical studies have shown 
that VEGF polymorphisms, and increased intra-tumoral 
VEGF gene expression correlates with poor p  rognosis.20 
Ovarian cancer tumor vasculature also tends to be structur-
ally and functionally abnormal, leaky and tortuous, with 
immature endothelial cells. These cells have increased 
dependence on VEGF for survival in comparison to mature 
vasculature.21,22
Two single-agent phase 2 bevacizumab trials have 
explored its utility in the treatment of recurrent, predominantly 
platinum-resistant, ovarian cancer. The first, GOG 170D, the 
largest single agent study, explored the use of bevacizumab 
at a dose of 15 mg/kg in patients with persistent or recurrent 
epithelial ovarian cancer or primary peritoneal cancer after 
1–2 prior cytotoxic regimens.23 The study consisted of 62 
eligible and assessable patients. Of these, 66.1% had received 
2 prior cytotoxic chemotherapy regimens, and 41.9% were 
considered platinum resistant. Thirteen patients (21.0%) 
experienced clinical responses (2 complete, 11   partial; median 
response duration, 10 months), and 25 (40.3%) survived 
progression free for at least 6 months. Median PFS and OS 
were 4.7 and 17 months, respectively. The second was an 
industry-sponsored trial evaluating the efficacy and safety 
of bevacizumab in patients with platinum-resistant epithelial 
ovarian carcinoma or peritoneal serous carcinoma who had 
experienced disease progression during or within 3 months of 
discontinuing topotecan or liposomal doxorubicin.24 Enrolled 
patients received single-agent bevacizumab 15 mg/kg every 
3 weeks, and nearly 84% were platinum resistant. Partial 
responses were observed in 15.9% with median PFS of 
4.4 months (95% CI: 3.1–5.5 months), and a median s  urvival 
duration of 10.7 months at study termination. This was 
f  ollowed by 2 trials combining cytotoxic chemotherapy with 
bevacizumab in the treatment of recurrent disease. The trials 
showed response rates of 24% each and 6-month progression-
free rates of 50% and 56%, respectively.25,26
The above phase 2 trials were then followed by 4 ran-
domized phase 3 trials, looking at bevacizumab as a first-line 
agent and in disease recurrence. Three of these trials have 
completed accrual, namely GOG 218, International collab-
orative ovarian neoplasm (ICON) 7, and OCEANS. GOG 218 
is a 3-arm placebo controlled study, with all patients r  eceiving 
carboplatin and paclitaxel. In the first experimental arm, 
patients were treated with concurrent bevacizumab followed 
by placebo maintenance, while in the third experimental arm, 
patients received concurrent and maintenance bevacizumab 
(15 mg/kg every 3 weeks) for up to 16 doses.27 A total of 
1873 patients were enrolled. Of these patients, 34% were 
optimally cytoreduced, with 40% suboptimally debulked, 
and 26% being stage 4. Preliminary data, as presented at 
the 2010 meeting for the American Society of Clinical 
Oncology (ASCO), showed a significant improvement in 
PFS in patients treated with concurrent and maintenance 
bevacizumab, 14.1 months vs 10.3 months in the placebo 
arm. Relative to arm 1 of the trial, the hazard ratio for first 
progression in the maintenance arm of the trial was 0.717 
(95% CI: 0.625–0.824, P , 0.0001). The OS data are not 
yet mature.
ICON-7 was a 2-armed trial comparing carboplatin 
and paclitaxel (6 cycles) against carboplatin + paclitaxel + 
bevacizumab (7.5 mg/kg) every 3 weeks for 6 cycles, fol-
lowed by 12 cycles of maintenance bevacizumab or disease 
progression, whichever occurred earlier. Data from this trial 
were presented in abstract form at the 2010 meeting of the 
European Society of Medical Oncology (ESMO). A total of 
1528 women were randomized from 263 centers. Adverse 
events were reported as consistent with previous bevaci-
zumab trials. More importantly, relative to arm 1 of the trial, 
the hazard ratio for disease progression in the bevacizumab 
arm was 0.81 (95% CI: 0.70–0.94, P , 0.0041).
The remaining phase III trials target patients with recur-
rent disease. GOG 213, is a randomized trial comparing 
carboplatin and paclitaxel with or without bevacizumab in 
platinum sensitive relapsed ovarian cancer patients. It also 
includes a study of secondary cytoreductive surgery in 
e  ligible patients. OCEANS, an industry-conducted study, is a 
randomized, placebo- controlled trial, comparing carboplatin 
and gemcitabine with or without bevacizumab in the treat-
ment of recurrent disease.7 This trial has completed accrual, 
but results are not available at this time (Table 1).
As with any new anti-tumor agent, the benefits of bevaci-
zumab in the treatment of patients with ovarian cancer must 
be weighed against the side effects. Overall, bevacizumab is 
well tolerated, with a side effect profile unique to its mode of 
action. In a comprehensive review, Randall et al investigated Biologics: Targets and Therapy 2011:5 submit your manuscript | www.dovepress.com
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the t  oxicities of bevacizumab in ovarian cancer patients, and 
their   management.7 Table 2 lists the adverse effects that were 
included in the FDA-approved bevacizumab package insert.28
The most common toxicities include hypertension (grade 
3–4 ranging from 0.3% to 14.8% of patients), proteinuria 
(usually grade 1–2), hemorrhage, arterial and venous throm-
botic events, impaired wound healing, and gastrointestinal 
perforation.18,29 Treatment strategies for bevacizumab related 
hypertension have yet to be defined, but traditional anti-
hypertensive agents including beta blockers, calcium channel 
blockers, and ACE inhibitors have successfully managed 
bevacizumab-related hypertension.
Bowel perforation is an additional feared adverse event 
and appears to be disease site-dependent, occurring in 
patients with mCRC and ovarian carcinoma. Ovarian cancer 
patients may be at increased risk due to the potential for bowel 
dysmotility and obstruction as a direct result of the disease 
process. Data from key phase II trials discussed previously 
indicated that patients who were heavily pretreated (3 or 
more previous cycles of cytotoxic chemotherapy) were at 
increased risk of bowel perforation. Although there were no 
reported gastrointestinal perforations (GIP) in GOG 170-D, 
eligible patients were limited to 1 or 2 previous chemotherapy 
regimens.23 Conversely, the phase II study completed by 
Cannistra et al was terminated early due to the high rate of 
GIP in the patient population, 11.4% (5 of 44 patients).24 
Importantly, all GIP occurred in patients receiving 3 or more 
previous chemotherapy regimens. We are awaiting final data 
from GOG 218 and ICON-7 to help elucidate risk in up-front 
treatment with bevacizumab.18
The management of bevacizumab toxicity requires 
individualized decision making that weighs drug efficacy 
against adverse event severity (grade) and potential long-
term consequences of both the adverse event and the disease. 
The goals of therapy (palliative vs curative), potential alterna-
tive therapies, cost, and patient quality of life should all be 
factored into these decisions. Communicating to the patient 
the complexity of issues that inform treatment decisions can 
aid in the management of expectations as well.
Conclusion
In summary, our understanding of the complex molecular 
pathways that control tumor angiogenesis continues to 
improve. The anti-VEGF agent bevacizumab has shown 
activity in the treatment of ovarian cancer, with an overall 
acceptable toxicity profile and is currently listed as an active 
treatment for recurrent ovarian and primary peritoneal c  ancers 
by the National Comprehensive Cancer Network, but it is 
not yet FDA-approved for these indications. B  evacizumab 
has been shown to exhibit a 15%–20% response rate with 
up to 50% PFS at 6 months in several phase II trials.23–26 
F  urthermore, the preliminary data from 2 phase III clinical 
trials, GOG 218 and ICON-7, show an improvement in PFS 
in the up-front treatment of ovarian cancer with the addition 
of bevacizumab. It is unclear, at this point in time, how these 
data will be applied clinically.
In the last decade, numerous biologic targets, including 
VEGF-inhibtors, epidermal growth factor receptor   inhibitors, 
poly-ADP-ribose polymerase inhibitors, and anti-folate 
agents have been identified and studies are under way to 
determine their utility in the treatment of ovarian cancer. 
Future studies exploring potential biomarkers to aid in 
Table 1 Randomized clinical trials evaluating bevacizumab in ovarian cancer
Study Trial design Status
First-line adjuvant therapy
GOG 218 Randomized, placebo-controlled, 3-arm, 
CT ± bev with 18-cycle bev maintenance 
Completed accrual: HR 0.717 favoring the concurrent 
and maintenance bevacizumab arm
ICON-7 Randomized, 2-arm, CT ± bev with 
12-cycle bev maintenance
Completed accrual: HR 0.80 favoring the concurrent 
and maintenance bevacizumab arm
Second-line therapy
GOG 213 Randomized, CT ± bev Open to accrual
OCEANS Randomized, placebo-controlled, CG ± bev Completed accrual July 2010: Results not yet available
Abbreviations: CT, carboplatin/paclitaxel; CG, carboplatin/gemcitabine; GOG, Gynecologic Oncology Group; ICON, International Collaborative Ovarian Neoplasm;   
bev, bevacizumab.
Table 2 Adverse events associated with bevacizumab
Adverse events
Common (mild) Rare (serious)
Headache Nongastrointestinal fistula formation
Hypertension Arterial thromboembolic events (myocardial 
infarction, cerebrovascular accident)
Proteinuria Gastrointestinal perforation
Wound healing complications
Reversible posterior leukoencephalopathy  
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p  redicting response to therapy (analogous to HER2 in breast 
cancer) are of utmost importance, as this will allow us to 
better select patients for therapy.
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